Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Prices Double For Multiple Molecules In December

Pricewatch UK – December 2022

Executive Summary

Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.

You may also be interested in...



UK Prices See A Raft Of Rises In November

Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.

France’s Gemme Claims A Victory With Price-Cut Reversal

French generics industry association Gemme has claimed a major victory in shifting the country’s policy on generic price cuts, after the government announced a moratorium on price reductions as well as targeted price increases for certain key locally-produced generics.

Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars

Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel